Search

Simple Summary: The initial treatment for patients with advanced-stage follicular lymphoma is usually a combo of immunochemotherapy called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-bendamustine (R-B, for short). After six cycles of R-CHOP, continuing with rituximab for two years (maintenance therapy) has demonstrated a reduction in relapses. However, determining if this approach works well after R-B has yet to be confirmed. Here, we collected data from 476 FL patients from 17 GELTAMO centers and evaluated the efficacy of both regimens followed by rituximab maintenance therapy in untreated follicular lymphoma patients. We found a better response with R-B and relapses were more frequent with R-CHOP. During the initial treatment, low blood counts were more frequent with R-CHOP but, during maintenance therapy, they were more frequent with R-B and so were infectious complications. After six years, 79% and 67% of R-B- and R-CHOP-treated patients, respectively, did not have evidence of the disease but the number of deaths was the same in both groups. In conclusion, R-B followed by rituximab maintenance therapy in patients with previously untreated follicular lymphoma showed better responses and fewer relapses, without any extra side effects in an elderly population. During maintenance, patients had more issues when using R-B but deaths were the same in both groups. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for maintenance therapy notably improves outcomes; however, whether this can be achieved by using the same approach after R-B therapy is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens followed by rituximab maintenance therapy for untreated advanced-stage FL. The complete response rate at the end of induction was higher with R-B and relapses were more frequent with R-CHOP. During induction, cytopenias were significantly more frequent with R-CHOP and so was the use of colony-stimulating factors. During maintenance therapy, R-B showed more neutropenia and infectious toxicity. After a median follow-up of 81 months (95% CI: 77–86), the 6-year rates of progression-free survival (PFS) were 79% (95% CI: 72–86) for R-bendamustine vs. 67% (95% CI: 61–73) for R-CHOP (p = 0.046), and 6-year overall survival (OS) values were 91% (95% CI: 86–96) for R-B vs. 91% (95% CI: 87–94) for R-CHOP (p = 0.49). In conclusion, R-B followed by rituximab maintenance therapy in patients with previously untreated FL resulted in significantly longer PFS than R-CHOP, with older patients also benefiting from this treatment without further toxicity. Adverse events during maintenance were more frequent with R-B without impacting mortality. [ABSTRACT FROM AUTHOR]

Summary: Nodal peripheral T‐cell lymphoma (PTCL) with a T follicular helper phenotype (PTCL‐TFH) is a new type of PTCL. We aimed to define its clinical characteristics and prognosis compared to PTCL not otherwise specified (PTCL‐NOS) and angioimmunoblastic T‐cell lymphoma (AITL). This retrospective observational study included 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites. Patient diagnosis was centrally reviewed, and patients were reclassified according to the World Health Organization (WHO) 2016 criteria: 21 patients as PTCL‐NOS, 55 as AITL and 23 as PTCL‐TFH. Median follow‐up was 56.07 months (95% CI 38.7–73.4). Progression‐free survival (PFS) and overall survival (OS) were significantly higher in patients with PTCL‐TFH than in those with PTCL‐NOS and AITL (PFS, 24.6 months vs. 4.6 and 7.8 months, respectively, p = 0.002; OS, 52.6 months vs. 10.0 and 19.3 months, respectively, p < 0.001). Histological diagnosis maintained an independent influence on both PFS (hazard ratio [HR] 4.1 vs. PTCL‐NOS, p = 0.008; HR 2.6 vs. AITL, p = 0.047) and OS (HR 5.7 vs. PTCL‐NOS, p = 0.004; HR 2.6 vs. AITL, p = 0.096), regardless of the International Prognostic Index. These results suggest that PTCL‐TFH could have more favourable features and prognosis than the other PTCL subtypes, although larger series are needed to corroborate these findings. [ABSTRACT FROM AUTHOR]

Summary: The aims of our study were to analyse compliance with the 2014 GELTAMO SMZL Guidelines, in patients with splenic marginal zone lymphoma (SMZL), and to evaluate the outcome according to the HPLLs/ABC‐adapted therapeutic strategy. Observational prospective multicenter study of 181 SMZL patients diagnosed between 2014 and 2020. Lymphoma‐specific survival (LSS), composite event‐free survival (CEFS) and response rates were assessed. 57% of the 168 patients included in the analysis followed the Guidelines. The overall response rate was higher in the rituximab chemotherapy and in the rituximab arms compared with the splenectomy arm (p < 0.001). The 5‐year overall survival was 77% and the 5‐year LSS of 93%. There were no differences in the 5‐year LSS according to the treatment received (p = 0.68). The 5‐year CEFS in the overall series was 45%, and there were significant differences between scores A and B (p = 0.036). There were no significant differences when comparing LSS and progression‐free survival in patients treated with rituximab or rituximab chemotherapy at diagnosis or after observation. Our data support HPLLs/ABC score as a practical tool for the management of SMZL, observation as the best approach for patients in group A and rituximab as the best treatment for group B. [ABSTRACT FROM AUTHOR]